← Back to Search

OCT-Guided C&D for Basal Cell Carcinoma

N/A
Waitlist Available
Led By Keyvan Nouri, MD
Research Sponsored by University of Miami
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Primary BCC of any type, except aggressive types that fit the criteria for Mohs surgery
Lesions anywhere except the head, neck and distal extremities.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months (post c&d procedure)
Awards & highlights

Study Summary

This trial uses OCT to see if there is any residual BCC after C&D, a treatment for the skin cancer.

Who is the study for?
This trial is open to individuals with basal cell carcinoma (BCC) who haven't had treatment on the lesion in the last 3 months. It's for all ages, genders, skin types, and ethnicities. The lesions should be primary BCC located anywhere but the head, neck, or distal extremities.Check my eligibility
What is being tested?
The study tests if optical coherence tomography (OCT), a non-invasive imaging test, can detect leftover superficial and nodular BCC after curettage & desiccation (C&D), which are common procedures to remove these skin cancers.See study design
What are the potential side effects?
Since OCT is a diagnostic procedure involving light waves to take pictures of tissue and C&D involves scraping away skin layers, potential side effects may include discomfort during imaging or post-procedure soreness and scarring at the treated site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a type of skin cancer called BCC, but it's not aggressive.
Select...
My cancer is not in my head, neck, or far limbs.
Select...
My age, gender, skin type, and ethnicity do not limit my participation.
Select...
I haven't had any treatments on the lesion in the last 3 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months (post c&d procedure)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 months (post c&d procedure) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The incidence of residual basal cell carcinoma tumor cells

Trial Design

1Treatment groups
Experimental Treatment
Group I: OCT Guided C&D GroupExperimental Treatment2 Interventions
Participants in this group will receive OCT imaging immediately prior, immediately after and 2 months after post standard of care C&D.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Optical Coherence Tomography (OCT)
2013
N/A
~1110

Find a Location

Who is running the clinical trial?

University of MiamiLead Sponsor
897 Previous Clinical Trials
409,260 Total Patients Enrolled
Keyvan Nouri, MDPrincipal InvestigatorUniversity of Miami
8 Previous Clinical Trials
107 Total Patients Enrolled

Media Library

Curettage & Desiccation (C&D) Procedure Clinical Trial Eligibility Overview. Trial Name: NCT04510727 — N/A
Basal Cell Carcinoma Research Study Groups: OCT Guided C&D Group
Basal Cell Carcinoma Clinical Trial 2023: Curettage & Desiccation (C&D) Procedure Highlights & Side Effects. Trial Name: NCT04510727 — N/A
Curettage & Desiccation (C&D) Procedure 2023 Treatment Timeline for Medical Study. Trial Name: NCT04510727 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there presently an open enrollment for participants in this research?

"The clinicaltrial.gov page for this study indicates that it is not currently enrolling, although the trial was initially opened on April 1st 2023 and last updated November 3rd 2022. Nonetheless, there are many other studies with open recruitment at present: 2 482 in total!"

Answered by AI
~0 spots leftby Feb 2025